Wednesday, July 8, 2026

Patent intelligence · US

US 6200958

Agent for treating high-risk impaired glucose tolerance

expired A61KA61K31/00A61K31/13A61K31/133
Status expired
Linked drugs 3
Pipeline programs 6
Years to expiry 0
Applicant portfolio 1,436
Patent details — US 6200958
Jurisdiction
US
Status
expired
Grant date
Mar 13, 2001
Expiration
Mar 8, 2021
Claims
9
CPC classes
A61K, A61K31/00, A61K31/13, A61K31/133
View on Google Patents ↗

Quick answer

US 6200958 (Agent for treating high-risk impaired glucose tolerance) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Mar 13, 2001. Expires Mar 8, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
9
CPC classes
A61K, A61K31/00, A61K31/13, A61K31/133, A61K31/7008

More from Takeda Chemical Industries Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 6200958?

US 6200958 (Agent for treating high-risk impaired glucose tolerance) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Mar 13, 2001. Expires Mar 8, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6200958?

Takeda Chemical Industries Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 6200958 expire?

Our index shows an expiration date of Mar 8, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.